📊 ESPR Key Takeaways
Is Esperion Therapeutics, Inc. (ESPR) a Good Investment?
Esperion faces severe balance sheet deterioration with negative stockholders' equity of -$307.9M and quarterly operating cash burn of -$27.7M, despite 21.3% revenue growth. While the company has adequate near-term liquidity ($156.2M cash), the trajectory toward insolvency and inability to achieve profitability at current operational scale presents substantial downside risk.
Esperion shows meaningful fundamental improvement, with 21.3% revenue growth, positive operating income, and a sharply narrower net loss, suggesting the commercial model is gaining traction. However, the business still posts negative net income and free cash flow, and the deeply negative equity position with liabilities far above assets materially weakens financial resilience. The fundamentals support cautious monitoring rather than a clearly bullish or bearish stance.
Why Buy Esperion Therapeutics, Inc. Stock? ESPR Key Strengths
- Strong revenue growth of 21.3% YoY demonstrates market adoption and commercialization progress
- Adequate liquidity with $156.2M cash providing approximately 2 years of operating runway at current burn rates
- Minimal debt burden ($140.0K long-term debt) eliminates near-term refinancing risk
- Revenue growth remains strong at 21.3% year over year, indicating improving commercial execution
- Operating margin of 15.0% and positive operating income show the core business is now generating operating profit
- Liquidity is still adequate near term, with $167.85M in cash and a 1.54x current ratio
ESPR Stock Risks: Esperion Therapeutics, Inc. Investment Risks
- Negative stockholders' equity of -$307.9M represents technical insolvency and indicates liabilities exceed all assets
- Operating cash flow of -$27.7M per quarter and widening net losses of -$25.2M show the company is not approaching profitability despite revenue growth
- Negative net margin of -31.5% indicates each dollar of revenue generates significant losses; cash runway is finite without profitability or capital raises
- Stockholders equity is deeply negative, reflecting an impaired balance sheet and limiting financial flexibility
- Net income and free cash flow remain negative, so the company has not yet demonstrated durable full-cycle profitability
- Total liabilities of $767.85M exceed total assets of $465.89M, creating elevated solvency risk if operating momentum weakens
Key Metrics to Watch
- Quarterly operating cash burn trend - critical to determine if burn rate is declining with scale
- Revenue growth sustainability - must maintain growth trajectory to justify cash consumption
- Gross margin percentage - currently unavailable but essential to understand product-level unit economics and path to profitability
- Sustained positive operating cash flow and free cash flow generation
- Net income margin improvement alongside liability reduction and equity stabilization
Esperion Therapeutics, Inc. (ESPR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Esperion Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ESPR Profit Margin, ROE & Profitability Analysis
ESPR vs Healthcare Sector: How Esperion Therapeutics, Inc. Compares
How Esperion Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Esperion Therapeutics, Inc. Stock Overvalued? ESPR Valuation Analysis 2026
Based on fundamental analysis, Esperion Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Esperion Therapeutics, Inc. Balance Sheet: ESPR Debt, Cash & Liquidity
ESPR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Esperion Therapeutics, Inc.'s revenue has grown significantly by 77% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.03 indicates the company is currently unprofitable.
ESPR Revenue Growth, EPS Growth & YoY Performance
ESPR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $65.0M | -$25.2M | $-0.10 |
| Q3 2025 | $51.6M | -$12.7M | $-0.15 |
| Q2 2025 | $73.8M | -$903.0K | $-0.01 |
| Q1 2025 | $65.0M | -$40.5M | $-0.21 |
| Q3 2024 | $34.0M | -$29.5M | $-0.15 |
| Q2 2024 | $25.8M | -$903.0K | $-0.01 |
| Q1 2024 | $24.3M | $61.0M | $0.34 |
| Q3 2023 | $19.0M | -$41.3M | $-0.37 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Esperion Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
ESPR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Esperion Therapeutics, Inc. (CIK: 0001434868)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ESPR
What is the AI rating for ESPR?
Esperion Therapeutics, Inc. (ESPR) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ESPR's key strengths?
Claude: Strong revenue growth of 21.3% YoY demonstrates market adoption and commercialization progress. Adequate liquidity with $156.2M cash providing approximately 2 years of operating runway at current burn rates. ChatGPT: Revenue growth remains strong at 21.3% year over year, indicating improving commercial execution. Operating margin of 15.0% and positive operating income show the core business is now generating operating profit.
What are the risks of investing in ESPR?
Claude: Negative stockholders' equity of -$307.9M represents technical insolvency and indicates liabilities exceed all assets. Operating cash flow of -$27.7M per quarter and widening net losses of -$25.2M show the company is not approaching profitability despite revenue growth. ChatGPT: Stockholders equity is deeply negative, reflecting an impaired balance sheet and limiting financial flexibility. Net income and free cash flow remain negative, so the company has not yet demonstrated durable full-cycle profitability.
What is ESPR's revenue and growth?
Esperion Therapeutics, Inc. reported revenue of $80.1M.
Does ESPR pay dividends?
Esperion Therapeutics, Inc. does not currently pay dividends.
Where can I find ESPR SEC filings?
Official SEC filings for Esperion Therapeutics, Inc. (CIK: 0001434868) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ESPR's EPS?
Esperion Therapeutics, Inc. has a diluted EPS of $-0.10.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ESPR a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Esperion Therapeutics, Inc. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ESPR stock overvalued or undervalued?
Valuation metrics for ESPR: ROE of N/A (sector avg: 15%), net margin of -31.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ESPR stock in 2026?
Our dual AI analysis gives Esperion Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ESPR's free cash flow?
Esperion Therapeutics, Inc.'s operating cash flow is $-27.7M, with capital expenditures of $189.0K. FCF margin is -34.8%.
How does ESPR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -31.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 1.53 (avg: 2).